Venture Investors raising $100 million fund

Madison firm invests in health care startups

Venture Investors LLC has filed notice with the SEC that it is raising a new $100 million venture capital fund.Coins stacked

The new fund is called Venture Investors Health 6 L.P. Madison-based Venture Investors has previously raised five other funds, which it has invested mainly in Midwestern health care startups, including several in the Milwaukee area. Established in 1997, Venture Investors has more than $200 million in assets under management, and 41 companies in its portfolio.

Its local portfolio companies are: then-Milwaukee-based Zystor Therapeutics Inc. (acquired by BioMarin Pharmaceutical for $115 million), which made therapeutics for lysosomal storage diseases; Wauwatosa-based TAI Diagnostics Inc., which has created an organ transplant monitoring blood test; then-Milwaukee-based GDXI, which offered trans-telephonic electrocardiogram services (acquired by Covance); and then-Brookfield-based Elucent Medical, which has created a breast tumor location guidance system.

According to the filing, Venture Investors has not yet raised any money for the new fund. Investors would receive pooled investment fund interests.

John Neis, executive managing director of Venture Investors, declined to comment on the new fund.

Venture Investors LLC has filed notice with the SEC that it is raising a new $100 million venture capital fund.Coins stacked

The new fund is called Venture Investors Health 6 L.P. Madison-based Venture Investors has previously raised five other funds, which it has invested mainly in Midwestern health care startups, including several in the Milwaukee area. Established in 1997, Venture Investors has more than $200 million in assets under management, and 41 companies in its portfolio.

Its local portfolio companies are: then-Milwaukee-based Zystor Therapeutics Inc. (acquired by BioMarin Pharmaceutical for $115 million), which made therapeutics for lysosomal storage diseases; Wauwatosa-based TAI Diagnostics Inc., which has created an organ transplant monitoring blood test; then-Milwaukee-based GDXI, which offered trans-telephonic electrocardiogram services (acquired by Covance); and then-Brookfield-based Elucent Medical, which has created a breast tumor location guidance system.

According to the filing, Venture Investors has not yet raised any money for the new fund. Investors would receive pooled investment fund interests.

John Neis, executive managing director of Venture Investors, declined to comment on the new fund.

Comments are closed.